An observational study in Severe Traumatic Brain Injury, sponsored by Corewell Health West. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Corewell Health West · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 198th largest by planned enrollment of the 257 observational ones that give a count, is one of 65 that started in 2026, is one of 258 observational ones, reaches primary completion later than 186 of the 249 other live ones, and was the 890th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:
Shirley Ryan AbilityLab · Sites in United States
Ages 18–75
Andrew Mayer · Sites in United States
Ages 18–82 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–55
Columbia University · Sites in United States
Ages 18+
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
909 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 110 · Phase 3 39 · Phase 4 28
First in 1996; this study’s year is marked. 65 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.
Median enrollment 50 across the 650 interventional studies, 120 across the 257 observational. Of the 553 that completed or were terminated, 182 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 909 have an industry lead sponsor. The 10 most frequent:
Corewell Health West is the lead sponsor of 16 studies on the registry; 9 are open to participants now.
Corewell Health West has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
83 of the studies in Brain Injuries, Traumatic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06368648CoMind Technologies LimitedCoMind Early Feasibility Study | 2026-11 |
| NCT06103201University of Maryland, BaltimoreHyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury | 2026-11-26 |
| NCT07733284Kessler FoundationHome-Based Walking for Thinking Skills in Persons With TBI | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT05702138Craig HospitalHigh Intensity Step Training After Traumatic Brain Injury | 2026-12 |
Add all 83 to your calendar (.ics) → With an account.
Among the 909 studies in Brain Injuries, Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe traumatic brain injury (sTBI) is a devastating condition with no targeted therapies available to prevent secondary injury. Previous studies have demonstrated that brain injury in adolescents initiates an acute and robust immune response characterized by disruption of the blood-brain barrier and the formation of autoantibodies.
Alterations in the gut-brain axis may contribute to increased immune activation and autoantibody formation following sTBI. The primary objective of this study is to better understand the immune mechanisms involved in the interaction between brain injury and changes in gut permeability through the gut-brain axis.
To investigate these mechanisms, the study will use a multi-platform metabolomics approach in combination with ribonucleic acid (RNA) sequencing, cell-free deoxyribonucleic acid (cfDNA) analysis, and blood chemistry. These analyses will be used to evaluate early immune activation and the mechanisms associated with secondary and tertiary brain injury and neurodegeneration in adults with sTBI.
Detailed Description
Severe traumatic brain injury (sTBI) is a devastating condition for which no targeted therapies currently exist. Current acute management strategies are largely focused on stabilizing cerebral physiology rather than addressing the molecular mechanisms responsible for injury progression.
The initial traumatic injury and subsequent secondary injury processes, including neuroinflammation, neurotoxicity, and disruption of the blood-brain barrier (BBB), may contribute to a robust autoimmune response. Pilot studies in adolescents have demonstrated activation of a strong immune response characterized by BBB disruption and autoantibody formation. This response may contribute to short- and long-term inflammatory sequelae, including exacerbation of the initial injury, progression to chronic neurodegenerative disease, increased disability, and mortality.
Alterations in the gut-brain axis may serve as a potential source of increased immunogenicity and subsequent autoantibody formation. The primary objective of this project is to define the immune mechanisms involved in the interaction between brain injury and alterations in gut permeability through the gut-brain axis.
Metabolomics comprehensively profiles and quantifies small-molecule metabolites produced by cells, tissues, and microorganisms, allowing for the evaluation of metabolic pathways and their roles in specific biological processes. Although several omics studies have characterized time-dependent changes in adults and experimental models, comparable studies using multi-omics approaches in sTBI remain limited. This represents an important gap in understanding the biological mechanisms involved in injury progression.
Lipids are essential to cellular function because of their roles in membrane composition, cellular signaling, and energy metabolism, particularly within the brain. Lipidomics, a subfield of metabolomics, identifies and quantifies lipids across cell types, organs, and organisms. Investigation of cellular lipid pathways and networks may provide important insight into the molecular mechanisms underlying traumatic brain injury (TBI). Emerging lipidomic studies suggest that circulating and central nervous system (CNS)-derived lipid signatures are associated with injury severity, BBB disruption, and long-term neurodegenerative risk. Therefore, lipidomics may provide important information for the comprehensive evaluation of sTBI pathogenesis.
The gut-brain axis is a bidirectional communication network between the gastrointestinal tract and CNS. It has been implicated in the pathophysiology of several neurodegenerative disorders and, more recently, in TBI. Following sTBI, rapid alterations may occur in gastrointestinal motility, epithelial barrier integrity, immune signaling, and microbial community structure. Collectively, these changes may result in gut dysbiosis and increased intestinal permeability, potentially due to diffuse mucosal barrier dysfunction.
Maintenance of gastrointestinal mucosal integrity requires coordinated interactions between the epithelial lining, associated cellular junctions, and immune mechanisms that regulate permeability and absorption. In contrast, the BBB is highly regulated and relatively impermeable under normal physiological conditions. Following brain injury, BBB permeability may increase, allowing the entry of molecules that would not typically cross the barrier. These peripheral disturbances may contribute to neuroinflammation, oxidative stress, and neurodegeneration. However, the precise mechanisms underlying these interactions remain unclear and are a primary focus of this study.
To identify the cells and molecular pathways involved in these alterations, single-cell RNA sequencing (scRNA-seq) will be combined with global metabolomics, with particular emphasis on identifying unique gut-derived metabolites, including bacterial products and food antigens that are not typically detected in serum. Single-cell RNA sequencing will be used to identify circulating cell types and clonal activation. These findings will be integrated with metabolomic data to further characterize the mechanisms through which increased gut permeability may contribute to neurotoxicity following sTBI.
This multi-omics approach is intended to develop a comprehensive model of the cellular and molecular mechanisms involved in the interaction between the gut and brain following sTBI. Ultimately, these findings may identify potential therapeutic targets aimed at reducing immune activation and attenuating secondary and tertiary brain injury.
Patients diagnosed with sTBI as defined as a Glascow Coma Scale (GCS) of 8 or less
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first cohort (Study Group) will consist of at least 20 patients admitted to CH Butterworth Hospital with a severe TBI, defined as a GCS ≤ 8 with evidence of intracranial pathology on imaging.
The second cohort (Trauma Control) will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury (head AIS 0).
Systemic immune and metabolic responses after sTBI
Characterize the circulating cellular transcriptome using Bulk RNA-seq and single-cell RNA sequencing ScRNA-seq, compared to trauma and healthy controls to identify circulating cell types, clonal activity, and antibody formation that contribute to injury progression.
Time frame: Time of injury and 1-month
Identifying the mechanisms of immune activation driving secondary injury
Define barrier disruption by performing both the 1H NMR and LC-MS metabolomic analysis (global, targeted, and lipidomics), transcriptomics, and proteomics to measure gut and blood-brain barrier permeability and markers of inflammation and neurodegeneration. Pinpoint cell types, pathways, and antibody-mediated mechanisms contributing to progressive brain injury by integrating transcriptomic and metabolomic datasets.
Time frame: 1 year
Establishment of a biorepository for future biomarker discovery and data integration with the sTBI patient registry for long-term follow-up.
Bank stool and oral flora samples to study gut dysbiosis and investigate the link between gut microbiome and TBI and longitudinal downstream metabolic consequences leading neurodegeneration and psychiatric pathologies· Bank bronchoalveolar lavage (when available), and plasma for additional future ScRNA analyses at defined timepoints. Establish longitudinal outcomes by leveraging a newly developed sTBI registry to follow patients over time, linking early immune and barrier changes with long-term risk of neurodegeneration.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.
Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 19 months is below that.
Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 23, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corewell Health West